Cost–consequence analysis of fluticasone furoate/vilanterol 92/22 mcg for the management of COPD in the Spanish NHS

Cost–consequence analysis of fluticasone furoate/vilanterol 92/22 mcg for the management of COPD in the Spanish NHS

Laura Amanda Vallejo-Aparicio,1 Germán Peces-Barba,2 Alicia Gil,3 Alicia Huerta Hernandez1 1Market Access, GlaxoSmithKline, Tres Cantos, Madrid, Spain; 2IIS-Fundación Jiménez Díaz. CIBERES, Madrid, Spain; 3Omakase Consulting, Barcelona, Spain Objectives: T...

Full description

Bibliographic Details
Main Authors: Vallejo-Aparicio LA, Peces-Barba G, Gil A, Huerta Hernandez A
Format: Article
Language:English
Published: Dove Medical Press 2018-09-01
Series:ClinicoEconomics and Outcomes Research
Subjects:
Cost-consequence analysis
Chronic Obstructive Pulmonary Disease
fluticasone furoate/vilanterol
COPD Salford Lung Study
Online Access:https://www.dovepress.com/cost-consequence-analysis-of-fluticasone-furoate-vilanterol-9222-mcg-f-peer-reviewed-article-CEOR

Internet

https://www.dovepress.com/cost-consequence-analysis-of-fluticasone-furoate-vilanterol-9222-mcg-f-peer-reviewed-article-CEOR

Similar Items